stoxline Quote Chart Rank Option Currency Glossary
Adverum Biotechnologies, Inc. (ADVM)
8.04  -0.21 (-2.55%)    05-17 16:00
Open: 8.17
High: 8.38
Volume: 1,794,547
Pre. Close: 8.25
Low: 7.86
Market Cap: 167(M)
Technical analysis
2024-05-17 4:43:46 PM
Short term     
Mid term     
Targets 6-month :  12.23 1-year :  14.12
Resists First :  10.47 Second :  12.09
Pivot price 9.48
Supports First :  7.86 Second :  6.53
MAs MA(5) :  8.62 MA(20) :  9.67
MA(100) :  13.35 MA(250) :  13.55
MACD MACD :  -1.1 Signal :  -1.1
%K %D K(14,3) :  4.1 D(3) :  5.4
RSI RSI(14): 22.6
52-week High :  29.7 Low :  7.4
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADVM ] has closed above bottom band by 0.8%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.43 - 8.52 8.52 - 8.56
Low: 7.69 - 7.8 7.8 - 7.86
Close: 7.92 - 8.09 8.09 - 8.19
Company Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Headline News

Thu, 16 May 2024
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Increases By 6.2% - MarketBeat

Sun, 12 May 2024
HC Wainwright Reiterates Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM) - Defense World

Fri, 10 May 2024
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) - Yahoo Finance

Fri, 10 May 2024
Adverum Biotechnologies: Q1 Earnings Snapshot - Houston Chronicle

Thu, 09 May 2024
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - GlobeNewswire

Fri, 03 May 2024
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 21 (M)
Held by Insiders 1.061e+007 (%)
Held by Institutions 1.2 (%)
Shares Short 890 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1812e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 437.9 %
Return on Equity (ttm) -32.2 %
Qtrly Rev. Growth 3.6e+006 %
Gross Profit (p.s.) 0
Sales Per Share -100.49
EBITDA (p.s.) 0
Qtrly Earnings Growth -11.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -91 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.09
Price to Cash Flow 0.85
Stock Dividends
Dividend 0
Forward Dividend 1.2e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android